    Curt Herberts | | ZoomInfo.com









Herberts Curt A. III - Insider Stock Trading - OpenInsider











Sector

All Sectors

Group by Sector


Aerospace
Agriculture
Automobile
Building
Business Services
Chemical
Electrical
Energy
Fashion
Financial
Food & Beverage
Fund
Healthcare
Household
Insurance
Machinery
Media
Metals
Mining
Other
Personal Services
Real Estate
Retail
Technology
Telecom
Transportation
Utility




Industry

All Industries

Group by Industry






Insiders
Filings


All
Purchases
Sales

CIK: 1691262 - Address: C/o Sangamo Therapeutics, Inc., Point Richmond Tech Ctr, 501 Canal Blvd., Richmond, CA 94804 4 results 

						Links
						


SECYahooGoogleFinvizTradingViewStockChartsStockTwitsDownload CSV 













TC
Stat
Stk
Ins
Fil
+d
+w
+m
+q
+h
+y
avg







Filing Date
T Date
Ticker
IssuerInc Sector
IndIndustry
Owner
oSt
Rel
Title
T
TVal
Price
L
Qty
oc
Own
H
r2y
r1y
r6m
r3m
r6w
r3w
r7d
r3d
f1d
f1w
f1m
f3m
f6m
f1y



7/14/17 20:067/14/17SGMOSangamo Therapeutics, IncDEHealthBioPrdBiological Products, (No DiagHerberts Curt A. IIICAOSr.VP,ChM.d13.9900121D
7/14/17 20:067/14/17SGMOSangamo Therapeutics, IncDEHealthBioPrdBiological Products, (No DiagHerberts Curt A. IIICAOSr.VP,ChS.d-15010.000-15-4221D
6/2/17 20:266/1/17SGMOSangamo Therapeutics, IncDEHealthBioPrdBiological Products, (No DiagHerberts Curt A. IIICAOSVP,CBOS-146.800-2-535D
5/15/17 19:425/11/17SGMOSangamo Therapeutics, IncDEHealthBioPrdBiological Products, (No DiagHerberts Curt A. IIICAOSVP,CBOS.m-218.0212-3-737D-343710811358918286



DDerivative transaction in filing (usually option exercise)
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
AAmended filing
EError detected in filing



S - SaleSale of securities on an exchange or to another person

S - Sale+OESale of securities on an exchange or to another person (after option exercise)

F - TaxPayment of exercise price or tax liability using portion of securities received from the company

P - PurchasePurchase of securities on an exchange or from another person


Return to top
Contact
Copyright © 2017 OpenInsider.com. All rights reserved.







Insider Trading - Herberts Curt A. III - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Herberts Curt A. III





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-12-12Tax Withholding
2016-12-148:11 pm
N/AN/A
Sangamo Biosciences Inc
SGMO
Herberts Curt A. IIISenior VP & CBO
4,852
$3.05
33,300(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 22:45:39 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  










	
        Compensation Information for Curt A. Herberts III, Senior Vice President and Chief Business Officer of SANGAMO THERAPEUTICS INC | Salary.com
    


























Enterprise
Small Business
Personal




Contact Us
Log In


































Salaries
Jobs
Education
Advice
























 





Curt A. Herberts III
Executive Compensation
As Senior Vice President and Chief Business Officer at SANGAMO THERAPEUTICS INC, Curt A. Herberts III made $362,261 in total compensation.  Of this total $289,375 was received as a salary, $72,886 was received as a bonus, $0 was received in stock options, $0 was awarded as stock and $0 came from other types of compensation. This information is according to proxy statements filed for the 2016 fiscal year. 


ENTER AN EXECUTIVE OR COMPANY NAME
New Search


Go



The chart on this page features a breakdown of the total annual pay for Curt A. Herberts III,  Senior Vice President and Chief Business Officer at SANGAMO THERAPEUTICS INC as reported in their proxy statements. 
Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. SANGAMO THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. SANGAMO THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.
Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.
Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.



Other Executives at this Company


Edward O. Lanphier II
H. Ward Wolff 
Edward R. Conner M,D.
Alexander D. Macrae M.B., Ch.B., Ph.D

Geoffrey M. Nichol M.B., Ch.B.






Curt A. Herberts III


Base Pay$289,375
Bonus + Incentive Comp$72,886
Total Cash Compensation$362,261


Stock Award Value$0
Option Award Value$0
Total Equity$0



Total Other$0



Total Compensation$362,261




Browse Executives by First Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z


Browse Companies by Company Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#



This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement. 
Use of Data / Disclaimer
The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.
What is a proxy statement?
A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.
The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.







    





 

 






     

privacy policy
terms of use
about us
contact us

©  Salary.com. All rights reserved.


US Salaries
Canadian Salaries
Purchase a Salary Report
Salaries by Category
Salaries by Income
Salaries by Industry
Popular Salaries
Negotiation Tips
Benefits Calculator
Search Job Openings
Job Openings by State
Job Openings by Category
Education by Career
Education by Level
Education by Major
Cost of Living Calculator
























 









Curt A. Herberts III - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Curt A. Herberts III
Sr.VP & Chief Business Officer at Sangamo


View Full Profile
Are you Curt A. Herberts III? Claim your profile


 


Sign up for Equilar Atlas and view Curt A. Herberts III's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Curt A. Herberts III's  network and community.
												FOLLOW changes in Curt A. Herberts III's employment and money-in-motion.
												CONNECT with Curt A. Herberts III through your network of contacts.
												








Curt A. Herberts III's Executive Work History


Current


Sr.VP & Chief Business Officer, 
Sangamo


Past
To view Curt A. Herberts III's complete executive work history, sign up now
Age
36

 
 


Curt A. Herberts III's Biography



Curt A. Herberts, III has served as Senior Vice President and Chief Business Officer since December 2016 and oversees Sangamo's business functions and plans for commercialization of its therapeutics. Mr. Herberts has over 10 years of experience in commercial strategy and corporate development. He joined Sangamo in October 2010 as Director, Corporate Development and Strategy and was promoted to Senior Director in January 2012, and Vice President and Head of Corporate Development in July 2015. During this time, Sangamo established a number of collaborative agreements, including global collaborations with Shire plc, in 2012, and Biogen, Inc., in ...
(Read More)

			Curt A. Herberts, III has served as Senior Vice President and Chief Business Officer since December 2016 and oversees Sangamo's business functions and plans for commercialization of its therapeutics. Mr. Herberts has over 10 years of experience in commercial strategy and corporate development. He joined Sangamo in October 2010 as Director, Corporate Development and Strategy and was promoted to Senior Director in January 2012, and Vice President and Head of Corporate Development in July 2015. During this time, Sangamo established a number of collaborative agreements, including global collaborations with Shire plc, in 2012, and Biogen, Inc., in 2014. Prior to joining Sangamo, Mr. Herberts held several positions of increasing responsibility at Campbell Alliance Group, Inc., including leadership roles in the corporate development and commercial strategy practice areas, from June 2006 to October 2010.  Mr. Herberts holds an A.B. in Human Biology from Stanford University and a M.B.S. from Keck Graduate Institute of Applied Life Sciences.
		
Source: Sangamo on 04/25/2017
		
	

 






Sign up for Equilar Atlas and view Curt A. Herberts III's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Curt A. Herberts III. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Curt A. Herberts III's  network and community.
												FOLLOW changes in Curt A. Herberts III's employment and money-in-motion.
												CONNECT with Curt A. Herberts III through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Curt A. Herberts III


















Curt A. Herberts III's Connections (14)





Sign up now to view Curt A. Herberts III's 14 connections »









Steven J. Mento
Dir., President, Chief Executive Officer and Acting Principal Financial Officer, Conatus Pharmaceuticals Inc.









William R. Ringo
Board Member, Immune Design Corp.









Dale G. Ando
Former Vice President, Therapeutic Development and Chief Medical Officer, Sangamo









Edward R. Conner
Senior Vice President and Chief Medical Officer, Sangamo









Henry W. Wolff
Former Executive Vice President and Chief Financial Officer, Sangamo









Joseph S. Zakrzewski
Board Member, Insulet Corporation









Edward O. Lanphier
Former President and Chief Executive Officer, Sangamo









Robert F. Carey
Executive Vice President and Chief Business Officer, Horizon Pharma Public Limited Company









Alexander D. Macrae
President and Chief Executive Officer, Sangamo









Geoffrey M. Nichol
Former Executive Vice President, Research and Development, Sangamo








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
















Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft











Curt A.  Herberts III - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











Curt A.  Herberts III
Check out list of companies and businesses related to Curt A.  Herberts III. Find out Curt A.  Herberts III address and contact details. View other people related to Curt A.  Herberts III - coworkers, colleagues, companions, etc.
Address:   

C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR. 501 CANAL BLVD RICHMOND 94804 CA




Companies related to Curt A.  Herberts III
CIKCompany NamePositionCompany Address0001001233SANGAMO THERAPEUTICS, INCSr.VP & Chief Business Officer 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND 94804




Curt A.  Herberts III on the Web
Persons related to Curt A.  Herberts III - SANGAMO THERAPEUTICS, INCNamePositionCityDALE G  ANDOVP, Therapeutic Dev. & CMO SOUTH SAN FRANCISCODALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDORICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDPETER  BLUFORDVP, Corporate Development RICHMONDRobert  CareyDirector DEERFIELDCASEY C  CASEVice President, Research RICHMONDCASEY C  CASEVP, Research & Operations RICHMONDPaul B  ClevelandDirector PALO ALTOPaul B  ClevelandDirector RICHMONDPaul B  ClevelandDirector RICHMONDEdward R.  ConnerSenior VP & CMO RICHMONDSTEPHEN GEORGE  DILLYDirector ALAMEDASTEPHEN GEORGE  DILLYDirector RICHMONDSTEPHEN GEORGE  DILLYDirector RICHMONDWILLIAM G  GERBERDirector BOTHELLWILLIAM G  GERBERDirector RICHMONDWILLIAM G  GERBERDirector RICHMONDWILLIAM G  GERBERDirector RICHMONDWILLIAM G  GERBERDirector RICHMONDWILLIAM G  GERBERDirector RICHMONDPhilip D  GregoryVice President, Research & CSO RICHMONDPhilip D  GregorySVP of Research & CSO RICHMONDPhilip D  GregorySVP, Research & CSO RICHMONDPhilip D  GregorySVP of Research & CSO RICHMONDPhilip D  GregoryVice President, Research RICHMONDPhilip D  GregoryVice President, Research RICHMONDPhilip D  GregoryVice President, Research RICHMONDPhilip D  GregoryCSO & Vice President, Research RICHMONDPhilip D  GregorySVP of Research & CSO RICHMONDPhilip D  GregoryCSO & Vice President, Research RICHMONDCurt A.  Herberts IIISr.VP & Chief Business Officer RICHMONDDavid G  IchikawaRICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDJON E M  JACOBYDirector LITTLE ROCKJON E M  JACOBYDirector RICHMONDROGER  JEFFSDirector Peter  KolchinskyBOSTONLeRoy C  Kopp10% Owner EDINAEDWARD O  LANPHIER IIDirector RICHMONDEDWARD O  LANPHIER IIRICHMONDEDWARD O  LANPHIER IIPres and Chief Ex Officer RICHMONDEDWARD O  LANPHIER IIPresident & Chief Exec Officer RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIRICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIRICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident and CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident and CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident and CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIRICHMONDEDWARD O  LANPHIER IIPres & Chief Ex Officer RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDMargaret  LiuDirector RICHMONDMargaret  LiuDirector RICHMONDSandy  MacraePresident and CEO RICHMONDSteven J  MentoDirector RICHMONDSteven J  MentoDirector RICHMONDSteven J  MentoDirector RICHMONDSteven J  MentoDirector RICHMONDSteven J  MentoDirector RICHMONDGEOFFREY  NICHOLExecutive Vice President, R&D PRINCETONGEOFFREY  NICHOLExecutive Vice President, R&D RICHMONDGEOFFREY  NICHOLExecutive Vice President, R&D RICHMONDGEOFFREY  NICHOLExecutive Vice President, R&D RICHMONDH STEWART  PARKERDirector SEATTLEH STEWART  PARKERDirector RICHMONDRA Capital Healthcare Fund LPBOSTONRA CAPITAL MANAGEMENT, LLC BOSTONRA CAPITAL MANAGEMENT, LLC BOSTONSaira  RamasastryDirector RICHMONDSaira  RamasastryDirector RICHMONDWILLIAM R  RINGODirector WILLIAM R  RINGODirector RICHMONDWILLIAM R  RINGODirector RICHMONDWILLIAM R  RINGORICHMONDWILLIAM J  RUTTERDirector THOMAS G  WIGGANSDirector RICHMONDTHOMAS G  WIGGANSDirector RICHMONDTHOMAS G  WIGGANSDirector RICHMONDHenry Ward  WolffExec VP & CFO FREMONTHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffDirector RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDMICHAEL C  WOODDirector MICHAEL C  WOODDirector RICHMONDMICHAEL C  WOODDirector RICHMONDMICHAEL C  WOODDirector RICHMONDKathy  YiSenior VP & CFO RICHMONDJoseph S  ZakrzewskiDirector SOMERSETGREG  ZANTESr Dir., Finance and Admin RICHMONDGREG  ZANTESr Dir., Finance & Admin RICHMONDGREG  ZANTESr. Director Finance & Admin RICHMONDGREG  ZANTEVP, Finance & Administration RICHMONDGREG  ZANTEVice President, Fin. & Admin. RICHMONDGREG  ZANTEVice President, Fin. & Admin. RICHMONDGREG  ZANTEVP, Finance & Administration RICHMOND












 









Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft












Sr.VP & Chief Business Officer of Sangamo Therapeutics (NASDAQ:SGMO), Herberts Curt A. Iii, sells 15,000 shares worth 0,000









































Stay Connected

Latest Posts in RSS

BusinessEntertainmentFeatured NewsFeatured Press ReleaseFinanceHealthLifestyleNationNon FirstPageOriginalPress ReleaseReviewShoppingSportsStocksTechnologyTravelWorld


Latest Comments in RSS


 / 













EmpoweredNews
World News Summary Helping You Stay Informed









Business
Finance
Sports
Entertainment
Health
Technology
Travel
Shopping




Our Writers
About Us
Privacy Policy
Contact Us
Advertise
Press Releases
















Sr.VP & Chief Business Officer of Sangamo Therapeutics (NASDAQ:SGMO), Herberts Curt A. Iii, sells 15,000 shares worth $150,000
According to Sangamo Therapeutics's most recent Form 4 filing with the SEC dated Jul 14 08:06 PM, company Sr.VP & Chief Business Officer, Herberts Curt A. Iii disclosed selling 15,000 shares at a cost of $10.00. At the time of this transaction (Jul 14), this trade was worth $150,000 in total. As of Jul 14, Herberts Curt A. Iii now owns 20,517 shares in total worth about $207,221.7. 
For the last few recent trades made by Sangamo Therapeutics (NASDAQ:SGMO) Sr.VP & Chief Business Officer, Herberts Curt A. Iii, we have the following information:




SEC Form 4 filing: Jun 01: Sold 2,000 shares at the rate of $6.80 per share. Total worth of this trade was $13,600. Total number of shares owned as of Jun 01 were 35,345
SEC Form 4 filing: May 11: Sold 639 shares at the rate of $6.50 per share. Total worth of this trade was $4,154. Total number of shares owned as of May 11 were 39,345
SEC Form 4 filing: May 12: Sold 2,000 shares at the rate of $8.50 per share. Total worth of this trade was $17,000. Total number of shares owned as of May 12 were 37,345




					Posted by  



George Daniels 

					
					on Saturday July 15 2017, 9:56 AM EDT. 

All trademarks acknowledged. 
Filed under Stocks.

	Comments closed, Trackbacks open.	
 Follow responses: 
RSS 2.0




Comments are closed


 Latest News 
Director of Centene Corporation (NYSE:CNC), Ditmore Robert K, sells 4,167 shares worth $344,153
Director of Alphabet Inc (NASDAQ:GOOG), Tilghman Shirley M, sells 525 shares worth $492,499
Exec VP & Chief Operating Off. of Plexus Corp (NASDAQ:PLXS), Frisch Steven J., sells 2,500 shares worth $137,043
PRESIDENT, CEO of Ciena Corporation (NYSE:CIEN), Smith Gary B, sells 4,000 shares worth $105,006
Director of Scientific Games Corp (NASDAQ:SGMS), Isaacs Michael Gavin, sells 68,036 shares worth $2,643,298
President & CEO of UConcrete (NASDAQ:USCR), Sandbrook William J, sells 6,500 shares worth $495,760
Senior EVP and CFO of Exelon Corporation (NYSE:EXC), Thayer Jonathan W, sells 202,950 shares worth $7,712,100
10% Owner of InfraREIT (NYSE:HIFR), Teachers Insurance & Annuity A, sells 42,735 shares worth $961,003
Director of Spark Energy (NASDAQ:SPKE), Maxwell W Keith Iii, sells 10,524 shares worth $222,126
EVP – Corporate Banking of BOK Financial Corporation (NASDAQ:BOKF), Kymes Stacy, sells 3,000 shares worth $255,180

 


News Categories 
Business (7)

Stocks (15,169)



Entertainment (1,297)

Featured News (3,486)

Featured Press Release (253,394)

Finance (309)

Health (653)

Lifestyle (19)

Nation (90)

Non FirstPage (2)

Original (47)

Press Release (17)

Review (1)

Shopping (267)

Sports (613)

Technology (194)

Travel (286)

World (1,367)


  Featured Press Releases 
Director of Centene Corporation (NYSE:CNC), Ditmore Robert K, sells 4,167 shares worth $344,153
Director of Alphabet Inc (NASDAQ:GOOG), Tilghman Shirley M, sells 525 shares worth $492,499
Exec VP & Chief Operating Off. of Plexus Corp (NASDAQ:PLXS), Frisch Steven J., sells 2,500 shares worth $137,043
PRESIDENT, CEO of Ciena Corporation (NYSE:CIEN), Smith Gary B, sells 4,000 shares worth $105,006
Director of Scientific Games Corp (NASDAQ:SGMS), Isaacs Michael Gavin, sells 68,036 shares worth $2,643,298
President & CEO of UConcrete (NASDAQ:USCR), Sandbrook William J, sells 6,500 shares worth $495,760
Senior EVP and CFO of Exelon Corporation (NYSE:EXC), Thayer Jonathan W, sells 202,950 shares worth $7,712,100
10% Owner of InfraREIT (NYSE:HIFR), Teachers Insurance & Annuity A, sells 42,735 shares worth $961,003
Director of Spark Energy (NASDAQ:SPKE), Maxwell W Keith Iii, sells 10,524 shares worth $222,126
EVP – Corporate Banking of BOK Financial Corporation (NASDAQ:BOKF), Kymes Stacy, sells 3,000 shares worth $255,180







Business
Finance
Sports
Entertainment
Health
Technology
Travel
Shopping
 

About Us
Contact Us
Privacy Policy
Advertise
Press Releases
Terms Of Service
 
Log in 












﻿
























Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III Sells 15,000 Shares - BNB Daily





































 
















 

 













Daily Ratings & News for Sangamo Therapeutics Inc.
Complete the form below to receive the latest headlines and analysts' recommendationsfor Sangamo Therapeutics Inc. with our free daily email newsletter:



 




Follow @bnbdailynews





Recent Posts

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III Sells 15,000 Shares
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 3,735 Shares
BidaskClub Upgrades Comfort Systems USA, Inc. (NYSE:FIX) to “Hold”
Insider Selling: Varian Medical Systems, Inc. (NYSE:VAR) EVP Sells 1,088 Shares of Stock
Synchrony Financial (SYF) Given “Buy” Rating at Instinet
BMO Capital Markets () Given Consensus Rating of “” by Analysts
JetBlue Airways Corporation (NASDAQ:JBLU) Receives Average Rating of “Hold” from Analysts
California Public Employees Retirement System Has $7.46 Million Position in Radian Group Inc. (NYSE:RDN)
Wheeler Real Estate Investment Trust (NASDAQ:WHLR) & Getty Realty Corporation (GTY) Head to Head Contrast
Blount International (NYSE:BLT) & Kennametal (KMT) Head to Head Contrast
Critical Analysis: Hudson Global (HSON) vs. On Assignment (ASGN)
Reviewing Invesco PLC (IVZ) and Silvercrest Asset Management Group (SAMG)
California Public Employees Retirement System Has $7.40 Million Position in Unisys Corporation (NYSE:UIS)
BMO Capital Markets () Receives Average Rating of “” from Brokerages
Superior Energy Services, Inc. (SPN) Downgraded to “Equal Weight” at Barclays PLC
StarTek, Inc. (SRT) Lowered to Hold at Zacks Investment Research
Safety Income & Growth Inc (SAFE) Earns “Neutral” Rating from Bank of America Corporation
Air Canada (AC) Price Target Raised to C$22.50
First Long Island Investors LLC Has $13.80 Million Position in The Charles Schwab Corporation (NYSE:SCHW)
Applied Industrial Technologies, Inc. (NYSE:AIT) Stake Reduced by California Public Employees Retirement System


 


Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III Sells 15,000 Shares

Posted by Stefani Robinson on Jul 27th, 2017 // No Comments 

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $10.00, for a total value of $150,000.00. Following the completion of the transaction, the vice president now directly owns 35,517 shares in the company, valued at $355,170. The sale was disclosed in a legal filing with the SEC, which is available through this link. 
Curt A. Herberts III also recently made the following trade(s): 





On Thursday, June 1st, Curt A. Herberts III sold 2,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $6.80, for a total value of $13,600.00. 
On Friday, May 12th, Curt A. Herberts III sold 2,639 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $8.02, for a total transaction of $21,164.78. 

Shares of Sangamo Therapeutics, Inc. (NASDAQ SGMO) traded down 5.99% during mid-day trading on Thursday, reaching $8.79. 928,901 shares of the company’s stock were exchanged. Sangamo Therapeutics, Inc. has a 52-week low of $2.65 and a 52-week high of $10.50. The company has a 50 day moving average price of $8.70 and a 200 day moving average price of $5.78. The firm’s market cap is $632.34 million. 


 Get Sangamo Therapeutics Inc. alerts:



Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.03. Sangamo Therapeutics had a negative net margin of 380.44% and a negative return on equity of 50.76%. The company had revenue of $3.40 million for the quarter, compared to analyst estimates of $4.14 million. During the same quarter last year, the firm earned ($0.23) EPS. The firm’s quarterly revenue was down 12.8% compared to the same quarter last year. Analysts forecast that Sangamo Therapeutics, Inc. will post ($0.93) earnings per share for the current fiscal year. 
WARNING: “Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III Sells 15,000 Shares” was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.baseball-news-blog.com/2017/07/27/sangamo-therapeutics-inc-nasdaqsgmo-vp-curt-a-herberts-iii-sells-15000-shares-updated.html. 
A number of analysts recently commented on the stock. Wedbush restated a “neutral” rating and issued a $4.00 price objective (down previously from $6.00) on shares of Sangamo Therapeutics in a research report on Tuesday, May 16th. Jefferies Group LLC reiterated a “buy” rating and set a $17.00 target price on shares of Sangamo Therapeutics in a report on Thursday, June 22nd. ValuEngine upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Finally, Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Sangamo Therapeutics has an average rating of “Hold” and a consensus target price of $8.50.
Several institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at $203,000. Aperio Group LLC purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at $108,000. Fox Run Management L.L.C. purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at $126,000. HighTower Advisors LLC boosted its stake in shares of Sangamo Therapeutics by 0.3% in the first quarter. HighTower Advisors LLC now owns 39,405 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 100 shares during the last quarter. Finally, Iguana Healthcare Management LLC purchased a new stake in shares of Sangamo Therapeutics during the first quarter valued at $780,000. 59.20% of the stock is currently owned by institutional investors. 
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. 
 
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 





















Latest News




Leave a Reply

Click here to cancel reply.




Name (Required) 



Mail (will not be published) (Required) 



Website






 






























